GlassScriptPhysician profile
Cyrus Badii
NPI 1134274350
$7,068.97
in general payments reported to CMS, 2019-2025
25 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $642 · 2022: $247 · 2023: $1,428 · 2024: $1,632 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,089.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,453.34 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $754.36 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $682.83 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $558.37 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $534.81 | 2020-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $432.88 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $381.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $373.04 | 2019 | |
| Genzyme Corporation | $337.28 | 2022-2025 | |
| Ardelyx, INC. | $273.12 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $271.09 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $183.94 | 2023-2024 | Dupixent |
| Novo Nordisk INC | $183.15 | 2025 | Wegovy |
| Evoke Pharma, INC. | $140.99 | 2022-2023 | Gimoti |
| Celgene Corporation | $129.51 | 2023-2024 | Zeposia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $64.03 | 2019-2025 | Sucraid |
| Capsovision, INC. | $52.19 | 2025 | Capsocam Plus |
| Boston Scientific Corporation | $43.15 | 2022 | |
| Gilead Sciences, INC. | $41.89 | 2020-2023 | |
| Concordia Pharmaceuticals INC. | $39.16 | 2019 | |
| Merck Sharp & Dohme LLC | $38.27 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $35.00 | 2020 | |
| Braintree Laboratories, INC. | $31.16 | 2020 | |
| Lucid Diagnostics INC. | $19.88 | 2023 | |
| Alfasigma USA, INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyrus Badii listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.